Prostate-Specific Antigen Density (PSAD)
ورودیهای بالینی بیمار
حداقل ۰.۱ — حداکثر ۱۰۰۰ • واحد: ng/mL
حداقل ۵ — حداکثر ۳۰۰ • واحد: cc
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low0–0.15
- Elevated0.15–100
The Prostate-Specific Antigen Density (PSAD) calculates evaluating lower urinary tract symptoms, nephrolithiasis burden, and prostate cancer risk. Key inputs include psa. Scores guide initiating medical expulsive or alpha-blocker therapy, ordering renal imaging, or scheduling surgical intervention. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
PSA divided by prostate volume; >= 0.15 ng/mL/cc raises suspicion for prostate cancer.
Clinical Indication
The Prostate-Specific Antigen Density (PSAD) is indicated for bedside clinical practice to support PSA divided by prostate volume; >= 0.15 ng/mL/cc raises suspicion for prostate cancer.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with renal colic, hematuria, benign prostatic hyperplasia (BPH), or urogenital malignancies. Clinical application is indicated across Urology clinics, shock wave lithotripsy suites, and acute urologic surgical services.
Limitations & Contraindications
Serum PSA levels can be transiently elevated by acute prostatitis, urinary retention, or recent instrumentation.
Clinical Pearls & Action Plan
Obstructive urolithiasis complicated by upper urinary tract infection represents a surgical emergency requiring urgent decompression.
PSAD = PSA (ng/mL) / prostate volume (cc)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| psa | float | Yes | Total PSA(ng/mL) |
| prostate_volume | float | Yes | Prostate volume (TRUS/MRI)(cc) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0.15 | Low | PSAD below 0.15 |
| 0.15–100 | Elevated | PSAD 0.15 or higher |
Evidence-Based References (EBM)
- Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147(3 Pt 2):815-816.